Skip to main content
Top
Published in: Critical Care 3/2009

Open Access 01-06-2009 | Research

Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial

Authors: Marcel Hochreiter, Thomas Köhler, Anna Maria Schweiger, Fritz Sixtus Keck, Berthold Bein, Tilman von Spiegel, Stefan Schroeder

Published in: Critical Care | Issue 3/2009

Login to get access

Abstract

Introduction

The development of resistance by bacterial species is a compelling issue to reconsider indications and administration of antibiotic treatment. Adequate indications and duration of therapy are particularly important for the use of highly potent substances in the intensive care setting. Until recently, no laboratory marker has been available to differentiate bacterial infection from viral or non-infectious inflammatory reaction; however, over the past years, procalcitonin (PCT) is the first among a large array of inflammatory variables that offers this possibility. The present study aimed to investigate the clinical usefulness of PCT for guiding antibiotic therapy in surgical intensive care patients.

Methods

All patients requiring antibiotic therapy based on confirmed or highly suspected bacterial infections and at least two concomitant systemic inflammatory response syndrome criteria were eligible. Patients were randomly assigned to either a PCT-guided (study group) or a standard (control group) antibiotic regimen. Antibiotic therapy in the PCT-guided group was discontinued, if clinical signs and symptoms of infection improved and PCT decreased to <1 ng/ml or the PCT value was >1 ng/ml, but had dropped to 25 to 35% of the initial value over three days. In the control group antibiotic treatment was applied as standard regimen over eight days.

Results

A total of 110 surgical intensive care patients receiving antibiotic therapy after confirmed or high-grade suspected infections were enrolled in this study. In 57 patients antibiotic therapy was guided by daily PCT and clinical assessment and adjusted accordingly. The control group comprised 53 patients with a standardized duration of antibiotic therapy over eight days. Demographic and clinical data were comparable in both groups. However, in the PCT group the duration of antibiotic therapy was significantly shorter than compared to controls (5.9 +/- 1.7 versus 7.9 +/- 0.5 days, P < 0.001) without negative effects on clinical outcome.

Conclusions

Monitoring of PCT is a helpful tool for guiding antibiotic treatment in surgical intensive care patients. This may contribute to an optimized antibiotic regimen with beneficial effects on microbial resistance and costs in intensive care medicine.

Annotation

Results were previously published in German in Anaesthesist 2008; 57: 571–577 (PMID: 18463831).

Trial registration

ISRCTN10288268
Appendix
Available only for authorised users
Literature
1.
go back to reference Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9CrossRefPubMed Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9CrossRefPubMed
2.
go back to reference ACCP/SCCM Consensus Conference Committee: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20: 864-874.CrossRef ACCP/SCCM Consensus Conference Committee: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20: 864-874.CrossRef
3.
go back to reference Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinkart K: Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999, 37: 363-368. 10.1515/CCLM.1999.060CrossRefPubMed Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinkart K: Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999, 37: 363-368. 10.1515/CCLM.1999.060CrossRefPubMed
4.
go back to reference Peres Bota D, Lopes Ferreira F, Mélot C, Vincent JL: Body temperature alterations in the critically ill. Intensive Care Med 2004, 30: 811-816. 10.1007/s00134-004-2166-zCrossRefPubMed Peres Bota D, Lopes Ferreira F, Mélot C, Vincent JL: Body temperature alterations in the critically ill. Intensive Care Med 2004, 30: 811-816. 10.1007/s00134-004-2166-zCrossRefPubMed
5.
go back to reference Bossink A, Groeneveld A, Hack C, Thijs L: The clinical host response to microbial infection in medical patients with fever. Clin Infect Dis 1999, 29: 398-407. 10.1086/520222CrossRefPubMed Bossink A, Groeneveld A, Hack C, Thijs L: The clinical host response to microbial infection in medical patients with fever. Clin Infect Dis 1999, 29: 398-407. 10.1086/520222CrossRefPubMed
6.
go back to reference Christ-Crain M, Müller B: Procalcitonin in bacterial infections – hype, hope, more or less? Swiss Medical Weekly 2005, 135: 451-460.PubMed Christ-Crain M, Müller B: Procalcitonin in bacterial infections – hype, hope, more or less? Swiss Medical Weekly 2005, 135: 451-460.PubMed
7.
go back to reference Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J, Geneva Sepsis Network: Diagnostic value of procalcitonin, interleukin 6 and interleukin 8 in critically ill patiens admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164: 396-402.CrossRefPubMed Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J, Geneva Sepsis Network: Diagnostic value of procalcitonin, interleukin 6 and interleukin 8 in critically ill patiens admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164: 396-402.CrossRefPubMed
8.
go back to reference Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community – acquired pneumonia. Am J Respir Crit Care Med 2006, 174: 84-93. 10.1164/rccm.200512-1922OCCrossRefPubMed Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community – acquired pneumonia. Am J Respir Crit Care Med 2006, 174: 84-93. 10.1164/rccm.200512-1922OCCrossRefPubMed
9.
go back to reference Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients. A randomized trial. Am J Respir Crit Care Med 2008, 177: 498-505. 10.1164/rccm.200708-1238OCCrossRefPubMed Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients. A randomized trial. Am J Respir Crit Care Med 2008, 177: 498-505. 10.1164/rccm.200708-1238OCCrossRefPubMed
10.
go back to reference Welte T: Antibiotikatherapie bei Sepsis. Dtsch Med Wochenschr 2004, 129: 2609-2613. 10.1055/s-2004-836084CrossRefPubMed Welte T: Antibiotikatherapie bei Sepsis. Dtsch Med Wochenschr 2004, 129: 2609-2613. 10.1055/s-2004-836084CrossRefPubMed
11.
go back to reference Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290: 2588-2598. 10.1001/jama.290.19.2588CrossRefPubMed Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290: 2588-2598. 10.1001/jama.290.19.2588CrossRefPubMed
12.
go back to reference Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162: 505-511.CrossRefPubMed Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162: 505-511.CrossRefPubMed
13.
go back to reference Yu V, Singh N: Excessive antimicrobial usage cause measurable harm to patients with suspected ventilator – associated pneumonia. Intensive Care Med 2004, 30: 735-738. 10.1007/s00134-004-2201-0CrossRefPubMed Yu V, Singh N: Excessive antimicrobial usage cause measurable harm to patients with suspected ventilator – associated pneumonia. Intensive Care Med 2004, 30: 735-738. 10.1007/s00134-004-2201-0CrossRefPubMed
14.
go back to reference Harbarth S: Antibiotikatherapie – Einfluss des Antibiotikaverbrauchs auf Resistenzbildung und – selektion. Anästhesiol Intensivmed Schmerzther 2007, 2: 130-135. 10.1055/s-2007-971165CrossRef Harbarth S: Antibiotikatherapie – Einfluss des Antibiotikaverbrauchs auf Resistenzbildung und – selektion. Anästhesiol Intensivmed Schmerzther 2007, 2: 130-135. 10.1055/s-2007-971165CrossRef
15.
go back to reference Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Caladra T, Glauser MP, Tauber MG, Pittet D: Fungal Infection Network of Switzerland. Epidermiology of candidemia in Swiss tertiary care hospitals: seculare trends, 1991–2000. Clin Infect Dis 2004, 38: 311-320. 10.1086/380637CrossRefPubMed Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Caladra T, Glauser MP, Tauber MG, Pittet D: Fungal Infection Network of Switzerland. Epidermiology of candidemia in Swiss tertiary care hospitals: seculare trends, 1991–2000. Clin Infect Dis 2004, 38: 311-320. 10.1086/380637CrossRefPubMed
16.
go back to reference Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22: 707-710. 10.1007/BF01709751CrossRefPubMed Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22: 707-710. 10.1007/BF01709751CrossRefPubMed
17.
go back to reference Engelmann L: Die Diagnose der Sepsis. In Diagnostik und Intensivtherapie bei Sepsis und Multiorganversagen. 1st edition. Edited by: Engelmann L, Schuster H-P. Darmstadt: Steinkopff; 2006:2-10.CrossRef Engelmann L: Die Diagnose der Sepsis. In Diagnostik und Intensivtherapie bei Sepsis und Multiorganversagen. 1st edition. Edited by: Engelmann L, Schuster H-P. Darmstadt: Steinkopff; 2006:2-10.CrossRef
18.
go back to reference Meisner M, Tschaikowsky K, Palmaers T, Schmidt J: Comparison of Procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of Sepsis and MODS. Critical Care 1999, 3: 45-50. 10.1186/cc306PubMedCentralCrossRefPubMed Meisner M, Tschaikowsky K, Palmaers T, Schmidt J: Comparison of Procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of Sepsis and MODS. Critical Care 1999, 3: 45-50. 10.1186/cc306PubMedCentralCrossRefPubMed
19.
go back to reference Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K: Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. Intensive Care Med 2007, 33: 606-618. 10.1007/s00134-006-0517-7CrossRefPubMed Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K: Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. Intensive Care Med 2007, 33: 606-618. 10.1007/s00134-006-0517-7CrossRefPubMed
20.
go back to reference Micek S, Heuring TJ, Hollands JM, Shah RA, Kollef MH: Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 2006, 26: 204-213. 10.1592/phco.26.2.204CrossRefPubMed Micek S, Heuring TJ, Hollands JM, Shah RA, Kollef MH: Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 2006, 26: 204-213. 10.1592/phco.26.2.204CrossRefPubMed
21.
go back to reference Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122: 262-268. 10.1378/chest.122.1.262CrossRefPubMed Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122: 262-268. 10.1378/chest.122.1.262CrossRefPubMed
22.
go back to reference Meyer E, Jonas D, Schwab F, Gastmeier P, Rüden H, Daschner FD: SARI: surveillance of antibiotic use and bacterial resistance in German intensive care units. Correlation between antibiotic use and the emergence of resistance. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004, 47: 345-351. 10.1007/s00103-004-0804-9CrossRefPubMed Meyer E, Jonas D, Schwab F, Gastmeier P, Rüden H, Daschner FD: SARI: surveillance of antibiotic use and bacterial resistance in German intensive care units. Correlation between antibiotic use and the emergence of resistance. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004, 47: 345-351. 10.1007/s00103-004-0804-9CrossRefPubMed
23.
go back to reference Welte T: Die nosokomiale Pneumonie. Intensivmed 2006, 43: 301-309. 10.1007/s00390-006-0721-2CrossRef Welte T: Die nosokomiale Pneumonie. Intensivmed 2006, 43: 301-309. 10.1007/s00390-006-0721-2CrossRef
Metadata
Title
Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial
Authors
Marcel Hochreiter
Thomas Köhler
Anna Maria Schweiger
Fritz Sixtus Keck
Berthold Bein
Tilman von Spiegel
Stefan Schroeder
Publication date
01-06-2009
Publisher
BioMed Central
Published in
Critical Care / Issue 3/2009
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc7903

Other articles of this Issue 3/2009

Critical Care 3/2009 Go to the issue